Diabetes is a lifestyle disease. Due to this, sugar level increases in the blood. Heart, brain and kidney are most needed in the body, so these organs have to bear the most due to diabetes.
Diabetes patients are growing rapidly worldwide. India is at the forefront of these. According to the International Diabetes Federation (IDF), 10.1 crore people in India are in the grip of diabetes. Most of whom are treating their medicine with their own pocket.
Type-2 diabetes is most commonly used in the drug called Empagliflozin. But the patent of Boehringer Ingelheim, which makes this drug, is ending on 11 March 2025. After this, Indian domestic pharmaceutical companies will launch it under their brand.
These include prominent drug -making companies like Mankind Pharma, Torrent, Alchem, Dr. Reddy and Lupine. The biggest thing is that Mankind Pharma is preparing to sell this medicine at a low price of up to 90% than the German company. If this happens, the medicine of 60 rupees will come for just 9 rupees.
According to health experts, Empaglogen is used in the treatment of diabetes, heart and kidney disease. More than 10.1 crore people in the country are diabetes. Most of which spend the cost of medicine from their pockets. In such a situation, they will get great relief due to decrease in the price of medicine.
According to the TOI report, Torrent Pharmaceuticals have already accepted 3 branded Empaglogen Drugs of Boharinger Ingelheim. According to Mankind Pharma, high quality raw material, which is USFDA certified. It has been able to further reduce the cost by using it and creating its own active pharmaceuticals ingredients. Since the cost of treating sugar patients in the country is high. Patients bear the expenses of their treatment on their own. In such a situation, the cheap of Empagliflozine can be very good for diabetes patients.
Published at: 11 Mar 2025 01:45 pm (IST)
